At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
ATI-450 +2 moredrug
Likely dose
Methotrexate 7.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating ATI-450, Placebo oral tablet, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 25 participants across 5 sites.
Detailed Summary
This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartMar 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedJan 30, 2020
Enrollment StartMar 16, 2020
Primary CompletionFeb 4, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.4 years ago
Interventions
ATI-450drug
Oral, small molecule MK2 inhibitor
Placebo oral tabletdrug
Placebo tablet manufactured to match ATI-450 in appearance
Methotrexatedrug
7.5 mg to 25 mg weekly